Table 4.
Adverse events.
| Adverse events | No. of studies | RR (95% CI) | p Value | Heterogeneity | |
|---|---|---|---|---|---|
| Nausea | 4 | 1.29 (0.45, 3.67) | 0.63 | χ 2 = 5.12, p = 0.16, I 2 = 41% | |
| A versus P | 2 | 1.29 (0.61, 2.69) | 0.5 | χ 2 = 0.74, p = 0.39, I 2 = 0% | |
| E versus P | 1 | 0.14 (0.01, 2.66) | 0.19 | — | |
| R versus P | 1 | 11.00 (0.64, 189.31) | 0.1 | — | |
| Rash | 3 | 2.03 (0.75, 5.52) | 0.16 | χ 2 = 0.12, p = 0.94, I 2 = 0% | |
| A versus P | 1 | 1.86 (0.61, 5.70) | 0.28 | — | |
| E versus P | 1 | 2.75 (0.12, 60.70) | 0.52 | — | |
| R versus P | 1 | 3.00 (0.13, 70.42) | 0.5 | — | |
| Diarrhea | 3 | 4.18 (1.70, 10.28) | 0.002 | χ 2 = 0.84, p = 0.66, I 2 = 0% | |
| A versus P | 3 | 4.18 (1.70, 10.28) | 0.002 | χ 2 = 0.84, p = 0.66, I 2 = 0% | |
| Abdominal pain | 2 | 6.11 (1.41, 26.52) | 0.02 | χ 2 = 0.08, p = 0.78, I 2 = 0% | |
| A versus P | 2 | 6.11 (1.41, 26.52) | 0.02 | χ 2 = 0.08, p = 0.78, I 2 = 0% | |
| Headache | A versus P | 2 | 0.69 (0.17, 2.77) | 0.6 | χ 2 = 0.95, p = 0.33, I 2 = 0% |
| A versus P | 2 | 0.69 (0.17, 2.77) | 0.6 | χ2 = 0.95, p = 0.33, I2 = 0% |
A: azithromycin; P: placebo; E: erythromycin; R: roxithromycin.